PCSK9 inhibitors: A new improvement for health

Clin Investig Arterioscler. 2019 Sep-Oct;31(5):241-243. doi: 10.1016/j.arteri.2018.11.001. Epub 2019 Feb 5.
[Article in English, Spanish]

Abstract

It is a patient with heterozygous familial hypercholesterolemia and a personal history of acute myocardial infarction, which is referred to our lipid unit for hypocholesterolemic treatment adjustment. Since he does not reach therapeutic goals with oral medication, he starts a treatment with fortnightly sessions of LDL-apheresis, which he keeps for 8 years. With the introduction and availability of PCSK9 inhibitors, a new treatment option is possible for this patient.

Keywords: Calidad de vida; Hipercolesterolemia; Hypercholesterolemia; Inhibidores de la PCSK9; PCSK9 inhibitors; Quality of life.

Publication types

  • Case Reports

MeSH terms

  • Anticholesteremic Agents / administration & dosage*
  • Anticholesteremic Agents / pharmacology
  • Blood Component Removal / methods
  • Cholesterol, LDL / blood
  • Humans
  • Hyperlipoproteinemia Type II / drug therapy
  • Hyperlipoproteinemia Type II / therapy*
  • Male
  • Middle Aged
  • PCSK9 Inhibitors*

Substances

  • Anticholesteremic Agents
  • Cholesterol, LDL
  • PCSK9 Inhibitors
  • PCSK9 protein, human